Metabolic syndrome is not uncommon among lean non-alcoholic fatty liver disease patients as compared with those with obesity

Sinha, Nirmalya Kumar; Mukhopadhyay, Saptarshi; Sau, Manabendra

doi:10.1007/s12664-020-01020-3

Cited by 7 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that Lean-NAFLD is a metabolically unhealthy status with especially high incidence among Asian population, and closely linked with various metabolic diseases including MS 17 and diabetes 18 . In this study, the baseline demographic characteristics of participants showed that TC present highest levels in lean NAFLD population.…”

Section: Discussionmentioning

confidence: 99%

Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study

Wang

Ren

Zhou

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Lean NAFLD is a special phenotypic closely correlated with metabolic syndrome (MS). The aim of this study is to investigate the MS development and the gender differences in lean NAFLD population. Participants were divided into 4 groups by BMI and NAFLD status. Descriptive analysis was performed to characterize baseline information. A total of 18,395 subjects were participated, and 1524 incident cases of MS were documented. Then, Kaplan–Meier curves were used to present the MS outcomes in different groups, and the NAFLD was found to be a riskier factor than obesity for MS. Subgroup analysis showed significantly higher MS incidence in female than male among lean NAFLD group, which is different from other groups. Although with higher prevalence in male, lean NAFLD seems to be a more harmful phenotype for females according to the TG, ALT and GGT levels. The logistic regressive analysis was performed to show the impact of NAFLD status and BMI changes on MS risk. Lean non-NAFLD subjects merely developed to NAFLD with no BMI status changes exhibited highest MS risk (ORs = 1.879, 95% CI 1.610–2.292) than that with both BMI increase and NAFLD development (ORs = 1.669, 95% CI 1.325–2.104). It also suggests the metabolic specificity of this population.

show abstract

Section: Discussionmentioning

confidence: 99%

Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study

Wang

Ren

Zhou

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Obese and lean NAFLD share many pathophysiological characteristics. For example, some individual components of MetS, such as high blood pressure, plasma glucose levels and serum triglycerides, appear to be similar between patients with obese or lean NAFLD, although MetS overall is more prevalent in obese cases 52 . The frequency of NASH and stage ≥2 fibrosis in nonobese NAFLD is 40% and 30%, respectively, 51 and neither appear to correlate with obesity 48 .…”

Section: Resultsmentioning

confidence: 99%

“…For example, some individual components of MetS, such as high blood pressure, plasma glucose levels and serum triglycerides, appear to be similar between patients with obese or lean NAFLD, although MetS overall is more prevalent in obese cases. 52 The frequency of NASH and stage ≥2 fibrosis in nonobese NAFLD is 40% and 30%, respectively, 51 and neither appear to correlate with obesity. 48 However, obese NAFLD may predict worse long-term prognosis due to higher transaminase levels, a higher degree of hepatic steatosis, and increased risk of metabolic complications and fibrosis, relative to nonobese NAFLD.…”

Section: Metabolic Dysfunctionmentioning

confidence: 99%

Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review

Cariou

Byrne

Loomba

et al. 2021

Diabetes Obesity Metabolism

138

104

View full text Add to dashboard Cite

Aims: To conduct a systematic literature review to identify recent epidemiological, biomarker, genetic and clinical evidence that expands our understanding of nonalcoholic fatty liver disease (NAFLD) as a metabolic disorder. Materials and Methods:We performed a literature search using PubMed to identify trials, observational studies and meta-analyses published in the past 5 years.Results: A total of 95 publications met prespecified inclusion criteria and reported on the interplay between NAFLD/nonalcoholic steatohepatitis (NASH) and metabolic dysfunction, in terms of disease burden and/or epidemiology (n = 10), pathophysiology, risk factors and associated conditions (n = 29), diagnosis and biomarkers (n = 34), and treatment approaches (n = 22). There is a growing body of evidence on the links between NAFLD/NASH pathogenesis and mechanisms of metabolic dysfunction, through liver lipid accumulation, insulin resistance, inflammation, apoptosis, and fibrogenic remodelling within the liver. The frequent co-occurrence of NAFLD with obesity, metabolic syndrome and type 2 diabetes supports this premise. Therapeutic approaches originally envisaged for type 2 diabetes or obesity (such as glucagon-like peptide-1 receptor agonists, sodium-glucose co-transporter-2 inhibitors, insulin sensitizers and bariatric surgery) have shown promising signs of benefit for patients with NAFLD/NASH.Conclusions: Given the complex interplay between NAFLD and metabolic dysfunction, there is an urgent need for multidisciplinary collaboration and established protocols for care of patients with NAFLD that are individualized and ideally support reduction of overall metabolic risk as well as treatment for NASH.

show abstract

“…A meta-analysis also showed a much weaker relationship between obesity and the incidence of severe liver diseases compared to other risk factors, such as insulin resistance and dyslipidemia ( 13 ). However, the incidence of metabolic syndromes is more prevalent in obese people ( 14 ), and NAFLD patients with obesity seem to have a poor prognosis ( 15 ). Obesity, or higher BMI, may contribute to NAFLD in a non-directive way, for example, through metabolic syndrome; this requires further in-depth study.…”

Section: Risk Factors Of Non-alcoholic Fatty Liver Diseasementioning

confidence: 99%

Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment

Che

Zhao

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

There is a continuously rising incidence of non-alcoholic fatty liver disease (NAFLD) around the world, which parallels the increasing incidence of metabolic diseases. NAFLD is a range of liver conditions that contains simple non-alcoholic fatty liver and advanced non-alcoholic steatohepatitis. In serious cases, NAFLD may develop into cirrhosis or even liver cancer. NAFLD has an intense relationship with metabolic syndrome, type 2 diabetes mellitus. It is known that gut microbiota, and functional molecules such as adenosine monophosphate-activated protein kinase JNK, and peroxisome proliferator-activated receptors (PPARs) in progressing and treating NAFLD. Traditionally, the conventional and effective therapeutic strategy is lifestyle intervention. Nowadays, new medicines targeting specific molecules, such as farnesoid X receptor, PPARs, and GLP-1 receptor, have been discovered and shown beneficial effects on patients with NAFLD. In this article, we focus on the molecular mechanisms and therapeutic approaches to NAFLD.

show abstract

Metabolic syndrome is not uncommon among lean non-alcoholic fatty liver disease patients as compared with those with obesity

Cited by 7 publications

References 33 publications

Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study

Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study

Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review

Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment

Contact Info

Product

Resources

About